Logo

Indications - Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC): After prior chemotherapy, or Who are considered cisplatin ineligibleand whose tumours have a PD-L1 expression ≥ 5%, or Who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression. Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer NSCLC after prior chemotherapy.

Dosage & Administration - General: Atezolizumab must be administered as an intravenousinfusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. Substitution by any other biological medicinal product requires the consent of the prescribing physician. The initial dose of Atezolizumab must be administered over 60 minutes. If the first infusion is tolerated all subsequent infusions may be administered over 30 minutes. The recommended dose of Atezolizumab is either: 1200 mg administered by IV infusion every 3 weeks or 1680 mg administered by IV infusion every 4 weeks. 1L cisplatin-ineligible mUC: Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test

Side Effects - Data not Show

Contraindications - Atezolizumab is contraindicated in patients with a known hypersensitivity to atezolizumab or any of the excipients.

Others - Pregnancy & Lactation There are no clinical studies of Atezolizumab in pregnant women. Atezolizumab is not recommended during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus It is not known whether Atezolizumab is excreted in human breast milk. No studies have been conducted to assess the impact of Atezolizumab on milk production or its presence in breast milk.Asthe potential for harm to the nursing infant is unknown,a decision must be madeto either discontinue breast-feeding ordiscontinue Atezolizumabtherapy.